Current issues in the diagnosis and management of adrenocortical carcinomas

References

• Young WF Jr. Clinical practice. The incidentally discovered adrenal mass. N. Engl. J. Med.356(6), 601–610 (2007).
   PubMed Web of Science ®Google Scholar
• Barzon L, Scaroni C, Sonino N, Fallo F, Paoletta A, Boscaro M. Risk factors and long-term follow-up of adrenal incidentalomas. J. Clin. Endocrinol. Metab.84(2), 520–526 (1999).
   PubMed Web of Science ®Google Scholar
• Wajchenberg BL, Albergaria Pereira MA, Medonca BB et al. Adrenocortical carcinoma: clinical and laboratory observations. Cancer88(4), 711–736 (2000).
   PubMed Web of Science ®Google Scholar
• Dackiw AP, Lee JE, Gagel RF, Evans DB. Adrenal cortical carcinoma. World J. Surg.25(7), 914–926 (2001).
   PubMed Web of Science ®Google Scholar
• Allolio B, Fassnacht M. Clinical review: adrenocortical carcinoma: clinical update. J. Clin. Endocrinol. Metab.91(6), 2027–2037 (2006).
   PubMed Web of Science ®Google Scholar
• Bellantone R, Ferrante A, Boscherini M et al. Role of reoperation in recurrence of adrenal cortical carcinoma: results from 188 cases collected in the Italian National Registry for Adrenal Cortical Carcinoma. Surgery122(6), 1212–1218 (1997).
   PubMed Web of Science ®Google Scholar
• Icard P, Goudet P, Charpenay C et al. Adrenocortical carcinomas: surgical trends and results of a 253-patient series from the French Association of Endocrine Surgeons study group. World J. Surg.25(7), 891–897 (2001).
   PubMed Web of Science ®Google Scholar
• Schulick RD, Brennan MF. Long-term survival after complete resection and repeat resection in patients with adrenocortical carcinoma. Ann. Surg. Oncol.6(8), 719–726 (1999).
   PubMed Web of Science ®Google Scholar
• Pommier RF, Brennan MF. An eleven-year experience with adrenocortical carcinoma. Surgery112(6), 963–970 (1992).
   PubMed Web of Science ®Google Scholar
• Stojadinovic A, Ghossein RA, Hoos A et al. Adrenocortical carcinoma: clinical, morphologic, and molecular characterization. J. Clin. Oncol.20(4), 941–950 (2002).
   PubMed Web of Science ®Google Scholar
• Terzolo M, Angeli A, Fassnacht M et al. Adjuvant mitotane treatment for adrenocortical carcinoma. N. Engl. J. Med.356(23), 2372–2380 (2007).
   PubMed Web of Science ®Google Scholar
• Bodie B, Novick AC, Pontes JE et al. The Cleveland Clinic experience with adrenal cortical carcinoma. J. Urol.141(2), 257–260 (1989).
   PubMed Web of Science ®Google Scholar
• Kasperlik-Zaluska AA, Migdalska BM, Zgliczynski S, Makowska AM. Adrenocortical carcinoma. A clinical study and treatment results of 52 patients. Cancer75(10), 2587–2591 (1995).
   PubMed Web of Science ®Google Scholar
• Luton JP, Cerdas S, Billaud L et al. Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy. N. Engl. J. Med.322(17), 1195–1201 (1990).
   PubMed Web of Science ®Google Scholar
• Kasperlik-Zaluska AA. Clinical results of the use of mitotane for adrenocortical carcinoma. Braz. J. Med. Biol. Res.33(10), 1191–1196 (2000).
   PubMed Web of Science ®Google Scholar
• Bilimoria KY, Shen WT, Elaraj D et al. Adrenocortical carcinoma in the United States: treatment utilization and prognostic factors. Cancer113(11), 3130–3136 (2008).
   PubMed Web of Science ®Google Scholar
• Cawood TJ, Hunt PJ, O’Shea D, Cole D, Soule S. Recommended evaluation of adrenal incidentalomas is costly, has high false-positive rates and confers a risk of fatal cancer that is similar to the risk of the adrenal lesion becoming malignant; time for a rethink? Eur. J. Endocrinol.161(4), 513–527 (2009).
   PubMed Web of Science ®Google Scholar
• Mansmann G, Lau J, Balk E, Rothberg M, Miyachi Y, Bornstein SR. The clinically inapparent adrenal mass: update in diagnosis and management. Endocr. Rev.25(2), 309–340 (2004).
   PubMed Web of Science ®Google Scholar
• Barzon L, Sonino N, Fallo F, Palu G, Boscaro M. Prevalence and natural history of adrenal incidentalomas. Eur. J. Endocrinol.149(4), 273–285 (2003).
   PubMed Web of Science ®Google Scholar
• Ng L, Libertino JM. Adrenocortical carcinoma: diagnosis, evaluation and treatment. J. Urol.169(1), 5–11 (2003).
   PubMed Web of Science ®Google Scholar
• Grumbach MM, Biller BM, Braunstein GD et al. Management of the clinically inapparent adrenal mass (“incidentaloma”). Ann. Intern. Med.138(5), 424–429 (2003).
   PubMed Web of Science ®Google Scholar
• Golden SH, Robinson KA, Saldanha I, Anton B, Ladenson PW. Clinical review: Prevalence and incidence of endocrine and metabolic disorders in the United States: a comprehensive review. J. Clin. Endocrinol. Metab.94(6), 1853–1878 (2009).
   PubMed Web of Science ®Google Scholar
• Ribeiro RC, Sandrini F, Figueiredo B et al. An inherited p53 mutation that contributes in a tissue-specific manner to pediatric adrenal cortical carcinoma. Proc. Natl Acad. Sci. USA98(16), 9330–9335 (2001).
   PubMed Web of Science ®Google Scholar
• Abiven G, Coste J, Groussin L et al. Clinical and biological features in the prognosis of adrenocortical cancer: poor outcome of cortisol-secreting tumors in a series of 202 consecutive patients. J. Clin. Endocrinol. Metab.91(7), 2650–2655 (2006).
   PubMed Web of Science ®Google Scholar
• Latronico AC, Chrousos GP. Extensive personal experience: adrenocortical tumors. J. Clin. Endocrinol. Metab.82(5), 1317–1324 (1997).
   PubMed Web of Science ®Google Scholar
• Luton JP, Martinez M, Coste J, Bertherat J. Outcome in patients with adrenal incidentaloma selected for surgery: an analysis of 88 cases investigated in a single clinical center. Eur. J. Endocrinol.143(1), 111–117 (2000).
   PubMed Web of Science ®Google Scholar
• Venkatesh S, Hickey RC, Sellin RV, Fernandez JF, Samaan NA. Adrenal cortical carcinoma. Cancer64(3), 765–769 (1989).
   PubMed Web of Science ®Google Scholar
• Barzilay JI, Pazianos AG. Adrenocortical carcinoma. Urol. Clin. North Am.16(3), 457–468 (1989).
   PubMed Web of Science ®Google Scholar
• Koch CA, Pacak K, Chrousos GP. The molecular pathogenesis of hereditary and sporadic adrenocortical and adrenomedullary tumors. J. Clin. Endocrinol. Metab.87(12), 5367–5384 (2002).
   PubMed Web of Science ®Google Scholar
• Lynch HT, Radford B, Lynch JF. SBLA syndrome revisited. Oncology47(1), 75–79 (1990).
   PubMed Web of Science ®Google Scholar
• Gonzalez KD, Noltner KA, Buzin CH et al. Beyond Li Fraumeni Syndrome: clinical characteristics of families with p53 germline mutations. J. Clin. Oncol.27(8), 1250–1256 (2009).
   PubMed Web of Science ®Google Scholar
• Mantero F, Terzolo M, Arnaldi G et al. A survey on adrenal incidentaloma in Italy. Study Group on Adrenal Tumors of the Italian Society of Endocrinology. J. Clin. Endocrinol. Metab.85(2), 637–644 (2000).
   PubMed Web of Science ®Google Scholar
• Didolkar MS, Bescher RA, Elias EG, Moore RH. Natural history of adrenal cortical carcinoma: a clinicopathologic study of 42 patients. Cancer47(9), 2153–2161(1981).
   PubMed Web of Science ®Google Scholar
• Libe R, Fratticci A, Bertherat J. Adrenocortical cancer: pathophysiology and clinical management. Endocr. Relat. Cancer14(1), 13–28 (2007).
   PubMed Web of Science ®Google Scholar
• Sandrini R, Ribeiro RC, DeLacerda L. Childhood adrenocortical tumors. J. Clin. Endocrinol. Metab.82(7), 2027–2031 (1997).
   PubMed Web of Science ®Google Scholar
• Mendonca BB, Lucon AM, Menezes CA et al. Clinical, hormonal and pathological findings in a comparative study of adrenocortical neoplasms in childhood and adulthood. J. Urol.154(6), 2004–2009 (1995).
   PubMed Web of Science ®Google Scholar
• Seccia TM, Fassina A, Nussdorfer GG, Pessina AC, Rossi GP. Aldosterone-producing adrenocortical carcinoma: an unusual cause of Conn’s syndrome with an ominous clinical course. Endocr. Relat. Cancer12(1), 149–159 (2005).
   PubMed Web of Science ®Google Scholar
• Kurtulmus N, Yarman S, Azizlerli H, Kapran Y. Co-secretion of aldosterone and cortisol by an adrenocortical carcinoma. Horm. Res.62(2), 67–70 (2004).
   PubMedGoogle Scholar
• Abma EM, Kluin PM, Dullaart RP. Malignant aldosterone-producing adrenal tumour: reoccurrence with glucocorticoid excess without hyperaldosteronism. Neth. J. Med.66(6), 252–255 (2008).
   PubMed Web of Science ®Google Scholar
• Nicol MR, Papacleovoulou G, Evans DB et al. Estrogen biosynthesis in human H295 adrenocortical carcinoma cells. Mol. Cell Endocrinol.300(1–2), 115–120 (2009).
   PubMed Web of Science ®Google Scholar
• Hyodo T, Megyesi K, Kahn CR, McLean JP, Friesen HG. Adrenocortical carcinoma and hypoglycemia: evidence for production of nonsuppressible insulin-like activity by the tumor. J. Clin. Endocrinol. Metab.44(6), 1175–1184 (1977).
   PubMed Web of Science ®Google Scholar
• Eguchi T, Tokuyama A, Tanaka Y et al. Hypoglycemia associated with the production of insulin-like growth factor II in adrenocortical carcinoma. Intern. Med.40(8), 759–763 (2001).
   PubMed Web of Science ®Google Scholar
• Sullivan M, Boileau M, Hodges CV. Adrenal cortical carcinoma. J. Urol.120(6), 660–665 (1978).
   PubMed Web of Science ®Google Scholar
• Grondal S, Eriksson B, Hagenas L, Werner S, Curstedt T. Steroid profile in urine: a useful tool in the diagnosis and follow up of adrenocortical carcinoma. Acta Endocrinol. (Copenh.)122(5), 656–663 (1990).
   PubMedGoogle Scholar
• Fassnacht M, Allolio B. Clinical management of adrenocortical carcinoma. Best Pract. Res. Clin. Endocrinol. Metab.23(2), 273–289 (2009).
   PubMed Web of Science ®Google Scholar
• Sawka AM, Jaeschke R, Singh RJ, Young WF Jr. A comparison of biochemical tests for pheochromocytoma: measurement of fractionated plasma metanephrines compared with the combination of 24-hour urinary metanephrines and catecholamines. J. Clin. Endocrinol. Metab.88(2), 553–558 (2003).
   PubMed Web of Science ®Google Scholar
• Lenders JW, Pacak K, Walther MM et al. Biochemical diagnosis of pheochromocytoma: which test is best? JAMA287(11), 1427–1434 (2002).
   PubMed Web of Science ®Google Scholar
• Korobkin M, Francis IR, Kloos RT, Dunnick NR. The incidental adrenal mass. Radiol. Clin. North Am.34(5), 1037–1054 (1996).
   PubMed Web of Science ®Google Scholar
• Hamrahian AH, Ioachimescu AG, Remer EM et al. Clinical utility of noncontrast computed tomography attenuation value (hounsfield units) to differentiate adrenal adenomas/hyperplasias from nonadenomas: Cleveland Clinic experience. J. Clin. Endocrinol. Metab.90(2), 871–877 (2005).
   PubMed Web of Science ®Google Scholar
• Gopan T, Remer E, Hamrahian AH. Evaluating and managing adrenal incidentalomas. Cleve. Clin. J. Med.73(6), 561–568 (2006).
   PubMed Web of Science ®Google Scholar
• Sturgeon C, Shen WT, Clark OH, Duh QY, Kebebew E. Risk assessment in 457 adrenal cortical carcinomas: how much does tumor size predict the likelihood of malignancy? J. Am. Coll. Surg.202(3), 423–430 (2006).
   PubMed Web of Science ®Google Scholar
• Boland GW, Lee MJ, Gazelle GS, Halpern EF, McNicholas MM, Mueller PR. Characterization of adrenal masses using unenhanced CT: an analysis of the CT literature. AJR Am. J. Roentgenol.171(1), 201–204 (1998).
   PubMed Web of Science ®Google Scholar
• Pena CS, Boland GW, Hahn PF, Lee MJ, Mueller PR. Characterization of indeterminate (lipid-poor) adrenal masses: use of washout characteristics at contrast-enhanced CT. Radiology217(3), 798–802 (2000).
   PubMed Web of Science ®Google Scholar
• Caoili EM, Korobkin M, Francis IR et al. Adrenal masses: characterization with combined unenhanced and delayed enhanced CT. Radiology222(3), 629–633 (2002).
   PubMed Web of Science ®Google Scholar
• Szolar DH, Korobkin M, Reittner P et al. Adrenocortical carcinomas and adrenal pheochromocytomas: mass and enhancement loss evaluation at delayed contrast-enhanced CT. Radiology234(2), 479–485 (2005).
   PubMed Web of Science ®Google Scholar
• Park BK, Kim CK, Kim B, Lee JH. Comparison of delayed enhanced CT and chemical shift MR for evaluating hyperattenuating incidental adrenal masses. Radiology243(3), 760–765 (2007).
   PubMed Web of Science ®Google Scholar
• Ilias I, Sahdev A, Reznek RH, Grossman AB, Pacak K. The optimal imaging of adrenal tumours: a comparison of different methods. Endocr. Relat. Cancer14(3), 587–599 (2007).
   PubMed Web of Science ®Google Scholar
• Okada M, Shimono T, Komeya Y et al. Adrenal masses: the value of additional fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) in differentiating between benign and malignant lesions. Ann. Nucl. Med.23(4), 349–354 (2009).
   PubMed Web of Science ®Google Scholar
• Boland GW, Blake MA, Holalkere NS, Hahn PF. PET/CT for the characterization of adrenal masses in patients with cancer: qualitative versus quantitative accuracy in 150 consecutive patients. AJR Am. J. Roentgenol.192(4), 956–962 (2009).
   PubMed Web of Science ®Google Scholar
• Murphy JJ, Tawfeeq M, Chang B, Nadel H. Early experience with PET/CT scan in the evaluation of pediatric abdominal neoplasms. J. Pediatr. Surg.43(12), 2186–2192 (2008).
   PubMed Web of Science ®Google Scholar
• Al-Hawary MM, Francis IR, Korobkin M. Non-invasive evaluation of the incidentally detected indeterminate adrenal mass. Best Pract. Res. Clin. Endocrinol. Metab.19(2), 277–292 (2005).
   PubMed Web of Science ®Google Scholar
• Caoili EM, Korobkin M, Brown RK, Mackie G, Shulkin BL. Differentiating adrenal adenomas from nonadenomas using 18F-FDG PET/CT: quantitative and qualitative evaluation. Acad. Radiol.14(4), 468–475 (2007).
   PubMed Web of Science ®Google Scholar
• Khan TS, Sundin A, Juhlin C, Langstrom B, Bergstrom M, Eriksson B. 11C-metomidate PET imaging of adrenocortical cancer. Eur. J. Nucl. Med. Mol. Imaging30(3), 403–410 (2003).
   PubMed Web of Science ®Google Scholar
• Hennings J, Lindhe O, Bergstrom M, Langstrom B, Sundin A, Hellman P. 11Cmetomidate positron emission tomography of adrenocortical tumors in correlation with histopathological findings. J. Clin. Endocrinol. Metab.91(4), 1410–1414 (2006).
   PubMed Web of Science ®Google Scholar
• Hahner S, Stuermer A, Kreissl M et al.123I iodometomidate for molecular imaging of adrenocortical cytochrome P450 family 11B enzymes. J. Clin. Endocrinol. Metab.93(6), 2358–2365 (2008).
   PubMed Web of Science ®Google Scholar
• Hennings J, Hellman P, Ahlstrom H, Sundin A. Computed tomography, magnetic resonance imaging and 11C-metomidate positron emission tomography for evaluation of adrenal incidentalomas. Eur. J. Radiol.69(2), 314–323 (2009).
   PubMed Web of Science ®Google Scholar
• Linos DA. Management approaches to adrenal incidentalomas (adrenalomas). A view from Athens, Greece. Endocrinol. Metab. Clin. North Am.29(1), 141–157 (2000).
   PubMed Web of Science ®Google Scholar
• Mody MK, Kazerooni EA, Korobkin M. Percutaneous CT-guided biopsy of adrenal masses: immediate and delayed complications. J. Comput. Assist. Tomogr.19(3), 434–439 (1995).
   PubMed Web of Science ®Google Scholar
• Mazzaglia PJ, Monchik JM. Limited value of adrenal biopsy in the evaluation of adrenal neoplasm: a decade of experience. Arch. Surg.144(5), 465–470 (2009).
   PubMedGoogle Scholar
• Quayle FJ, Spitler JA, Pierce RA, Lairmore TC, Moley JF, Brunt LM. Needle biopsy of incidentally discovered adrenal masses is rarely informative and potentially hazardous. Surgery142(4), 497–502 (2007).
   PubMed Web of Science ®Google Scholar
• Weiss LM, Medeiros LJ, Vickery AL Jr. Pathologic features of prognostic significance in adrenocortical carcinoma. Am. J. Surg. Pathol.13(3), 202–206 (1989).
   PubMed Web of Science ®Google Scholar
• Aubert S, Wacrenier A, Leroy X et al. Weiss system revisited: a clinicopathologic and immunohistochemical study of 49 adrenocortical tumors. Am. J. Surg. Pathol.26(12), 1612–1619 (2002).
   PubMed Web of Science ®Google Scholar
• Volante M, Buttigliero C, Greco E, Berruti A, Papotti M. Pathological and molecular features of adrenocortical carcinoma: an update. J. Clin. Pathol.61(7), 787–793 (2008).
   PubMed Web of Science ®Google Scholar
• Goldblum JR, Shannon R, Kaldjian EP et al. Immunohistochemical assessment of proliferative activity in adrenocortical neoplasms. Mod. Pathol.6(6), 663–668 (1993).
   PubMed Web of Science ®Google Scholar
• Vargas MP, Vargas HI, Kleiner DE, Merino MJ. Adrenocortical neoplasms: role of prognostic markers MIB-1, P53, and RB. Am. J. Surg. Pathol.21(5), 556–562 (1997).
   PubMed Web of Science ®Google Scholar
• Terzolo M, Boccuzzi A, Bovio S et al. Immunohistochemical assessment of Ki-67 in the differential diagnosis of adrenocortical tumors. Urology57(1), 176–182 (2001).
   PubMed Web of Science ®Google Scholar
• Wachenfeld C, Beuschlein F, Zwermann O et al. Discerning malignancy in adrenocortical tumors: are molecular markers useful? Eur. J. Endocrinol.145(3), 335–341 (2001).
   PubMed Web of Science ®Google Scholar
• Morimoto R, Satoh F, Murakami O et al. Immunohistochemistry of a proliferation marker Ki67/MIB1 in adrenocortical carcinomas: Ki67/MIB1 labeling index is a predictor for recurrence of adrenocortical carcinomas. Endocr. J.55(1), 49–55 (2008).
   PubMed Web of Science ®Google Scholar
• Soon PS, Gill AJ, Benn DE et al. Microarray gene expression and immunohistochemistry analyses of adrenocortical tumors identify IGF2 and Ki-67 as useful in differentiating carcinomas from adenomas. Endocr. Relat. Cancer16(2), 573–583 (2009).
   PubMed Web of Science ®Google Scholar
• Waldmann J, Feldmann G, Slater EP et al. Expression of the zinc-finger transcription factor Snail in adrenocortical carcinoma is associated with decreased survival. Br. J. Cancer99(11), 1900–1907 (2008).
   PubMed Web of Science ®Google Scholar
• Gupta D, Shidham V, Holden J, Layfield L. Value of topoisomerase II a, MIB-1, p53, E-cadherin, retinoblastoma gene protein product, and HER-2/neu immunohistochemical expression for the prediction of biologic behavior in adrenocortical neoplasms. Appl. Immunohistochem. Mol. Morphol.9(3), 215–221 (2001).
   PubMedGoogle Scholar
• Khorram-Manesh A, Ahlman H, Jansson S, Nilsson O. N-cadherin expression in adrenal tumors: upregulation in malignant pheochromocytoma and downregulation in adrenocortical carcinoma. Endocr. Pathol.13(2), 99–110 (2002).
   PubMed Web of Science ®Google Scholar
• Tissier F, Louvel A, Grabar S et al. Cyclin E correlates with malignancy and adverse prognosis in adrenocortical tumors. Eur. J. Endocrinol.150(6), 809–817 (2004).
   PubMed Web of Science ®Google Scholar
• Sasano H, Suzuki T, Moriya T. Recent advances in histopathology and immunohistochemistry of adrenocortical carcinoma. Endocr. Pathol.17(4), 345–354 (2006).
   PubMed Web of Science ®Google Scholar
• Tacon LJ, Soon PS, Gill AJ et al. The glucocorticoid receptor is overexpressed in malignant adrenocortical tumors. J. Clin. Endocrinol. Metab.94(11), 4591–4599 (2009).
   PubMed Web of Science ®Google Scholar
• Gicquel C, Leblond-Francillard M, Bertagna X et al. Clonal analysis of human adrenocortical carcinomas and secreting adenomas. Clin. Endocrinol. (Oxf.)40(4), 465–477 (1994).
   PubMed Web of Science ®Google Scholar
• Sidhu S, Marsh DJ, Theodosopoulos G et al. Comparative genomic hybridization analysis of adrenocortical tumors. J. Clin. Endocrinol. Metab.87(7), 3467–3474 (2002).
   PubMed Web of Science ®Google Scholar
• Stephan EA, Chung TH, Grant CS et al. Adrenocortical carcinoma survival rates correlated to genomic copy number variants. Mol. Cancer Ther.7(2), 425–431 (2008).
   PubMed Web of Science ®Google Scholar
• Soon PS, McDonald KL, Robinson BG, Sidhu SB. Molecular markers and the pathogenesis of adrenocortical cancer. Oncologist13(5), 548–561 (2008).
   PubMed Web of Science ®Google Scholar
• Gicquel C, Bertagna X, Gaston V et al. Molecular markers and long-term recurrences in a large cohort of patients with sporadic adrenocortical tumors. Cancer Res.61(18), 6762–6767 (2001).
   PubMed Web of Science ®Google Scholar
• Suh I, Guerrero MA, Kebebew E. Gene-expression profiling of adrenocortical carcinoma. Expert Rev. Mol. Diagn.9(4), 343–351 (2009).
   PubMed Web of Science ®Google Scholar
• de Reyniès A, Assie G, Rickman DS et al. Gene expression profiling reveals a new classification of adrenocortical tumors and identifies molecular predictors of malignancy and survival. J. Clin. Oncol.27(7), 1108–1115 (2009).
   PubMed Web of Science ®Google Scholar
• Giordano TJ, Kuick R, Else T et al. Molecular classification and prognostication of adrenocortical tumors by transcriptome profiling. Clin. Cancer Res.15(2), 668–676 (2009).
   PubMed Web of Science ®Google Scholar
• Gicquel C, Bertagna X, Schneid H et al. Rearrangements at the 11p15 locus and overexpression of insulin-like growth factor-II gene in sporadic adrenocortical tumors. J. Clin. Endocrinol. Metab.78(6), 1444–1453 (1994).
   PubMed Web of Science ®Google Scholar
• Barlaskar FM, Spalding AC, Heaton JH et al. Preclinical targeting of the type I insulin-like growth factor receptor in adrenocortical carcinoma. J. Clin. Endocrinol. Metab.94(1), 204–212 (2009).
   PubMed Web of Science ®Google Scholar
• Almeida MQ, Fragoso MC, Lotfi CF et al. Expression of insulin-like growth factor-II and its receptor in pediatric and adult adrenocortical tumors. J. Clin. Endocrinol. Metab.93(9), 3524–3531 (2008).
   PubMed Web of Science ®Google Scholar
• Fernandez-Ranvier GG, Weng J, Yeh RF et al. Candidate diagnostic markers and tumor suppressor genes for adrenocortical carcinoma by expression profile of genes on chromosome 11q13. World J. Surg.32(5), 873–881 (2008).
   PubMed Web of Science ®Google Scholar
• Fenske W, Volker HU, Adam P et al. Glucose transporter GLUT1 expression is an stage-independent predictor of clinical outcome in adrenocortical carcinoma. Endocr. Relat. Cancer16(3), 919–928 (2009).
   PubMed Web of Science ®Google Scholar
• Macfarlane DA. Cancer of the adrenal cortex; the natural history, prognosis and treatment in a study of fifty-five cases. Ann. R Coll. Surg. Engl.23(3), 155–186 (1958).
   PubMedGoogle Scholar
• Hogan TF, Gilchrist KW, Westring DW, Citrin DL. A clinical and pathological study of adrenocortical carcinoma: therapeutic implications. Cancer45(11), 2880–2883 (1980).
   PubMed Web of Science ®Google Scholar
• Haak HR, Hermans J, van de Velde CJ et al. Optimal treatment of adrenocortical carcinoma with mitotane: results in a consecutive series of 96 patients. Br. J. Cancer69(5), 947–951 (1994).
   PubMed Web of Science ®Google Scholar
• Soreide JA, Brabrand K, Thoresen SO. Adrenal cortical carcinoma in Norway, 1970–1984. World J. Surg.16(4), 663–667 (1992).
   PubMed Web of Science ®Google Scholar
• Schulick RD, Brennan MF. Adrenocortical carcinoma. World J. Urol.17(1), 26–34 (1999).
   PubMed Web of Science ®Google Scholar
• Fassnacht M, Johanssen S, Quinkler M et al. Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma: proposal for a Revised TNM Classification. Cancer115(2), 243–250 (2009).
   PubMed Web of Science ®Google Scholar
• Crucitti F, Bellantone R, Ferrante A, Boscherini M, Crucitti P. The Italian Registry for Adrenal Cortical Carcinoma: analysis of a multiinstitutional series of 129 patients. The ACC Italian Registry Study Group. Surgery119(2), 161–170 (1996).
   PubMed Web of Science ®Google Scholar
• Henley DJ, van Heerden JA, Grant CS, Carney JA, Carpenter PC. Adrenal cortical carcinoma – a continuing challenge. Surgery94(6), 926–931 (1983).
   PubMed Web of Science ®Google Scholar
• Assie G, Antoni G, Tissier F et al. Prognostic parameters of metastatic adrenocortical carcinoma. J. Clin. Endocrinol. Metab.92(1), 148–154 (2007).
   PubMed Web of Science ®Google Scholar
• Berruti A, Terzolo M, Sperone P et al. Etoposide, doxorubicin and cisplatin plus mitotane in the treatment of advanced adrenocortical carcinoma: a large prospective Phase II trial. Endocr. Relat. Cancer12(3), 657–666 (2005).
   PubMed Web of Science ®Google Scholar
• King DR, Lack EE. Adrenal cortical carcinoma: a clinical and pathologic study of 49 cases. Cancer44(1), 239–244 (1979).
   PubMed Web of Science ®Google Scholar
• Chiche L, Dousset B, Kieffer E, Chapuis Y. Adrenocortical carcinoma extending into the inferior vena cava: presentation of a 15-patient series and review of the literature. Surgery139(1), 15–27 (2006).
   PubMed Web of Science ®Google Scholar
• Schteingart DE, Doherty GM, Gauger PG et al. Management of patients with adrenal cancer: recommendations of an international consensus conference. Endocr. Relat. Cancer12(3), 667–680 (2005).
   PubMed Web of Science ®Google Scholar
• Kendrick ML, Lloyd R, Erickson L et al. Adrenocortical carcinoma: surgical progress or status quo? Arch. Surg.136(5), 543–549 (2001).
   PubMedGoogle Scholar
• Bertherat J, Coste J, Bertagna X. Adjuvant mitotane in adrenocortical carcinoma. N. Engl. J. Med.357(12), 1256–1257 (2007).
   PubMed Web of Science ®Google Scholar
• Rhim H, Dodd GD III, Chintapalli KN et al. Radiofrequency thermal ablation of abdominal tumors: lessons learned from complications. Radiographics24(1), 41–52 (2004).
   PubMed Web of Science ®Google Scholar
• Brown DB. Concepts, considerations, and concerns on the cutting edge of radiofrequency ablation. J. Vasc. Interv. Radiol.16(5), 597–613 (2005).
   PubMed Web of Science ®Google Scholar
• Wood BJ, Abraham J, Hvizda JL, Alexander HR, Fojo T. Radiofrequency ablation of adrenal tumors and adrenocortical carcinoma metastases. Cancer97(3), 554–560 (2003).
   PubMed Web of Science ®Google Scholar
• Soga H, Takenaka A, Ooba T et al. A twelve-year experience with adrenal cortical carcinoma in a single institution: long-term survival after surgical treatment and transcatheter arterial embolization. Urol. Int.82(2), 222–226 (2009).
   PubMed Web of Science ®Google Scholar
• Terzolo M, Berruti A. Adjunctive treatment of adrenocortical carcinoma. Curr. Opin. Endocrinol. Diabetes Obes.15(3), 221–226 (2008).
   PubMed Web of Science ®Google Scholar
• Baudin E, Pellegriti G, Bonnay M et al. Impact of monitoring plasma 1,1-dichlorodiphenildichloroethane (o,p’DDD) levels on the treatment of patients with adrenocortical carcinoma. Cancer92(6), 1385–1392 (2001).
   PubMed Web of Science ®Google Scholar
• Schteingart DE. Adjuvant mitotane therapy of adrenal cancer – use and controversy. N. Engl. J. Med.356(23), 2415–2418 (2007).
   PubMed Web of Science ®Google Scholar
• Martz F, Straw JA. The in vitro metabolism of 1-(O-chlorophenyl)-1-(P-chlorophenyl)-2,2-dichloroethane (o,p’-DDD) by dog adrenal mitochondria and metabolite covalent binding to mitochondrial macromolecules: a possible mechanism for the adrenocorticolytic effect. Drug Metab. Dispos.5(5), 482–486 (1977).
   PubMed Web of Science ®Google Scholar
• Hague RV, May W, Cullen DR. Hepatic microsomal enzyme induction and adrenal crisis due to o,p’DDD therapy for metastatic adrenocortical carcinoma. Clin. Endocrinol. (Oxf.)31(1), 51–57 (1989).
   PubMed Web of Science ®Google Scholar
• Daffara F, De FS, Reimondo G et al. Prospective evaluation of mitotane toxicity in adrenocortical cancer patients treated adjuvantly. Endocr. Relat. Cancer15(4), 1043–1053 (2008).
   PubMed Web of Science ®Google Scholar
• Alexandraki KI, Kaltsas GA, le Roux CW et al. Assessment of serum free cortisol levels in patients with adrenocortical carcinoma treated with mitotane: a pilot study. Clin. Endocrinol. (Oxf.)72(3), 305–311 (2009).
   PubMed Web of Science ®Google Scholar
• Faggiano A, Leboulleux S, Young J, Schlumberger M, Baudin E. Rapidly progressing high o,p’DDD doses shorten the time required to reach the therapeutic threshold with an acceptable tolerance: preliminary results. Clin. Endocrinol. (Oxf.)64(1), 110–113 (2006).
   PubMed Web of Science ®Google Scholar
• Terzolo M, Pia A, Berruti A et al. Low-dose monitored mitotane treatment achieves the therapeutic range with manageable side effects in patients with adrenocortical cancer. J. Clin. Endocrinol. Metab.85(6), 2234–2238 (2000).
   PubMed Web of Science ®Google Scholar
• Khan TS, Imam H, Juhlin C et al. Streptozocin and o,p’DDD in the treatment of adrenocortical cancer patients: long-term survival in its adjuvant use. Ann. Oncol.11(10), 1281–1287 (2000).
   PubMed Web of Science ®Google Scholar
• Biller BM, Grossman AB, Stewart PM et al. Treatment of adrenocorticotropin-dependent Cushing’s syndrome: a consensus statement. J. Clin. Endocrinol. Metab.93(7), 2454–2462 (2008).
   PubMed Web of Science ®Google Scholar
• Shalet S, Mukherjee A. Pharmacological treatment of hypercortisolism. Curr. Opin. Endocrinol. Diabetes Obes.15(3), 234–238 (2008).
   PubMedGoogle Scholar
• Contreras P, Rojas A, Biagini L, Gonzalez P, Massardo T. Regression of metastatic adrenal carcinoma during palliative ketoconazole treatment. Lancet2(8447), 151–152 (1985).
   PubMed Web of Science ®Google Scholar
• Shaw MA, Nicholls PJ, Smith HJ. Aminoglutethimide and ketoconazole: historical perspectives and future prospects. J. Steroid Biochem.31(1), 137–146 (1988).
   PubMedGoogle Scholar
• Castinetti F, Fassnacht M, Johanssen S et al. Merits and pitfalls of mifepristone in Cushing’s syndrome. Eur. J. Endocrinol.160(6), 1003–1010 (2009).
   PubMed Web of Science ®Google Scholar
• Polat B, Fassnacht M, Pfreundner L et al. Radiotherapy in adrenocortical carcinoma. Cancer115(13), 2816–2823 (2009).
   PubMed Web of Science ®Google Scholar
• Fassnacht M, Hahner S, Polat B et al. Efficacy of adjuvant radiotherapy of the tumor bed on local recurrence of adrenocortical carcinoma. J. Clin. Endocrinol. Metab.91(11), 4501–4504 (2006).
   PubMed Web of Science ®Google Scholar
• Haluska P, Worden F, Olmos D et al. Safety, tolerability, and pharmacokinetics of the anti-IGF-1R monoclonal antibody figitumumab in patients with refractory adrenocortical carcinoma. Cancer Chemother. Pharmacol.65(4), 765–773 (2009).
   PubMed Web of Science ®Google Scholar
• de FF, El AM, Gicquel C, Bertagna X, Chambaz EM, Feige JJ. Expression of the angiogenesis markers vascular endothelial growth factor-A, thrombospondin-1, and platelet-derived endothelial cell growth factor in human sporadic adrenocortical tumors: correlation with genotypic alterations. J. Clin. Endocrinol. Metab.85(12), 4734–4741 (2000).
   PubMed Web of Science ®Google Scholar
• Gross DJ, Munter G, Bitan M et al. The role of imatinib mesylate (Glivec) for treatment of patients with malignant endocrine tumors positive for c-kit or PDGF-R. Endocr. Relat. Cancer13(2), 535–540 (2006).
   PubMed Web of Science ®Google Scholar
• Chacon R, Tossen G, Loria FS, Chacon M. CASE 2. Response in a patient with metastatic adrenal cortical carcinoma with thalidomide. J. Clin. Oncol.23(7), 1579–1580 (2005).
   PubMed Web of Science ®Google Scholar
• Lee JO, Lee KW, Kim CJ et al. Metastatic adrenocortical carcinoma treated with sunitinib: a case report. Jpn J. Clin. Oncol.39(3), 183–185 (2009).
   PubMed Web of Science ®Google Scholar
• Doghman M, Cazareth J, Douguet D, Madoux F, Hodder P, Lalli E. Inhibition of adrenocortical carcinoma cell proliferation by steroidogenic factor-1 inverse agonists. J. Clin. Endocrinol. Metab.94(6), 2178–2183 (2009).
   PubMed Web of Science ®Google Scholar
• Harrison LE, Gaudin PB, Brennan MF. Pathologic features of prognostic significance for adrenocortical carcinoma after curative resection. Arch. Surg.134(2), 181–185 (1999).
   PubMed Web of Science ®Google Scholar
• Icard P, Chapuis Y, Andreassian B, Bernard A, Proye C. Adrenocortical carcinoma in surgically treated patients: a retrospective study on 156 cases by the French Association of Endocrine Surgery. Surgery112(6), 972–979 (1992).
   PubMed Web of Science ®Google Scholar
• Vassilopoulou-Sellin R, Schultz PN. Adrenocortical carcinoma. Clinical outcome at the end of the 20th Century. Cancer92(5), 1113–1121 (2001).
   PubMed Web of Science ®Google Scholar